← Eichor
Study identifier: NCT06781034 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies

Condition: Cerebral Hemorrhage · Acute Lobar Haematoma  ·  Sponsor: Centre Hospitalier Universitaire de Nīmes

PhaseN/A
Planned participants128
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment. Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis. An equivalent marker has also been described in gadolinium-enhanced MRI. By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.

This description comes directly from the study's public registry record.

Talk to the study team

Teodora PARVU  ·  04.66.68.32.61  ·  teodora.parvu@chu-nimes.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de NîmesNîmes, Gard, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06781034